<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184078</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1258</org_study_id>
    <nct_id>NCT02184078</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients</brief_title>
  <official_title>An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the effects of nevirapine on the steady state pharmacokinetics of
      rifabutin and to assess the steady state pharmacokinetics of nevirapine when given in
      combination with rifabutin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <primary_completion_date type="Actual">December 1998</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax,ss (maximum observed concentration at steady state)</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose at day 14 and day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin,ss (minimum observed concentration at steady state)</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose at day 14 and day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax,ss (Time of Cmax at steady state)</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose at day 14 and day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve over the dosing interval</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose at day 14 and day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F (apparent total clearance)</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose at day 14 and day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patient with adverse events</measure>
    <time_frame>up to day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>single group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nevirapine:
Study days 15-28 dose given once a day (q.d.) Study days 29-42 dose given twice a day (b.i.d.)
Rifabutin:
Study Days 0 to 42</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <arm_group_label>single group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <arm_group_label>single group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between the ages of 18 and 65 years who are seropositive for
             HIV-1 antibody by an ELISA test and confirmed by an alternative method e.g. Western
             Blot

          -  Lymphocytes Expressing CD4+ Surface Marker (CD4+ cell count) &gt;= 100 cells/mm³

          -  Patients must be taking at least 2 antiretroviral agents (with the exception of
             ritonavir, nelfinavir and non-nucleoside reverse transcriptase inhibitors taken
             continuously for at least 28 days prior to study entry (Day 0)

          -  Patients currently being treated with rifabutin during the screening period may be
             included provided that patients are receiving 300 mg once daily (or 150 mg once daily
             for patients concomitantly taking Zidovudine (ZDV), saquinavir or indinavir) and that
             there has been no change in dosing of &gt; 25% within 28 days prior to Study Day 0

          -  Patients who meet the following laboratory parameter:

               -  Granulocyte count &gt; 1000 cells/mm³

               -  Hemoglobin &gt; 9.0 g/dl (men and women)

               -  Platelet count &gt; 75000 cells/mm3

               -  Alkaline Phosphatase &lt; 3.0 times the upper limit of normal

               -  Serum Glutamic-Oxaloacetic Transaminase (SGOT) and Serum Glutamic-Pyruvic
                  Transaminase (SGPT) &lt; 3.0 times the upper limit of normal

               -  Total bilirubin &lt; 1.5 times the upper limit of normal

          -  Female patients of childbearing potential must be willing to use a reliable form of
             contraception which must include a medically form of barrier contraception

          -  Patients able to provide written consent and comply with study requirements

        Exclusion Criteria:

          -  Female patients who are pregnant or breast-feeding

          -  Seated systolic blood pressure below 100 mmHg or greater than 150 mmHg and/or heart
             rate less than 50 or greater than 90 beats/min.

          -  History of drug allergy or known drug hypersensitivity

          -  Patients receiving any investigational drug, antineoplastic agent or radiotherapy
             other than local skin radiotherapy treatment within 12 weeks before starting study
             medication

          -  Patients requiring systemic treatment with corticosteroids or drugs known to be
             hepatic enzyme inducers or inhibitors within 14 days of study entry (Study Day 0).
             Such substances in theses categories include: macrolide antibiotics (erythromycin,
             clarithromycin, azithromycin) azole antifungals (ketoconazole, fluconazole,
             itraconazole) rifampin and phenytoin

          -  Use of ritonavir, nelfinavir or non-nucleoside reverse transcriptase inhibitors within
             28 days of Study Day 0 or during the trial

          -  Patients with clinical evidence of active tuberculosis (TB) or undergoing treatment or
             prophylaxis for TB

          -  Patients with a current history of intravenous drug abuse, alcohol or substance abuse
             (within the last year)

          -  History of any clinically important disease including hepatic, renal, cardiovascular
             or gastrointestinal

          -  Patients with malabsorption, severe chronic diarrhea or subject unable to maintain
             adequate oral intake

          -  Patients with no previous antiretroviral background therapy taken continuously for the
             28 days prior to study entry (Day 0)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

